RxDoctor Payments Data

Hun Kang, MD

Family Medicine · Los Angeles, CANPI 1982645438

Payments from drug & device makers

$10,256in general payments, 2019–2025

Across 492 payments — averaging $20.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AbbVie$1K
  • Novo Nordisk$643
  • Bayer$607
  • Lilly USA, LLC$558
  • Pfizer$506
  • plus $5K from 39 others

What the payments were for

  • Food & beverage$10,243100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,256 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$195,172
Medicare patients
163
Services billed
3,084

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase184$216,325
ZenpepLipase/Protease/Amylase128$188,855
JardianceEmpagliflozin249$169,055
ProliaDenosumab84$141,647
KerendiaFinerenone170$121,228
LinzessLinaclotide165$95,639
FarxigaDapagliflozin Propanediol108$76,722
TradjentaLinagliptin125$75,226
JanuviaSitagliptin Phosphate101$70,009
EliquisApixaban74$60,530
RybelsusSemaglutide60$56,858
GemtesaVibegron99$55,497
XareltoRivaroxaban72$51,114
AfrezzaInsulin Regular, Human39$37,661
Evenity (2 Syringes)Romosozumab-Aqqg14$33,156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Restasis$1,194$331,587380 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy$388$251,486386 claims
AmgenProlia, Evenity (2 Syringes)$1,446$174,80398 claims
BayerKerendia$607$121,228170 claims
MerckJanuvia, Janumet$307$90,089123 claims
AstraZenecaFarxiga$403$76,722108 claims
PfizerEliquis$506$60,53074 claims
Novo NordiskRybelsus$643$56,85860 claims
Sumitomo Pharma America, Inc.Gemtesa$212$55,49799 claims
GSKShingrix, Trelegy Ellipta$271$52,568176 claims
Johnson & JohnsonXarelto$70$51,11472 claims
Mannkind CorporationAfrezza$346$37,66139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →